Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024 - a new market research report on companiesandmarkets.com
PR-Inside.com: 2014-04-03 00:31:01
The world market for retinal drugs will reach $9.8bn in 2017. Revenues are forecast to rise with double-digit growth during the forecast period.By 2017, the Eylea drug is forecast to attain revenue market shares of 29% of the macular degeneration and retinal diseases market. The Eylea drug has exceeded expectations to date, capturing a large share of the wAMD patient population, rather than merely becoming a salvage/second-line option (as may have been expected for a drug with similar mechanism of action and similar efficacy to the existing standard of care). Eylea´s slightly lower cost and superior label dosing schedule, combined with the apparent ill-will generated by some attempts to protect Lucentis. The relative goodwill of physicians towards the Regeneron product may seem subjective, but analysts have been informed off the record that this was a strong initial driver for Eylea´s uptake. Eylea´s longer-term growth prospects face the ongoing restraint of Lucentis getting to other retinal disease indications first; and the constant presence of Avastin as a lower-cost off-label option. Eylea´s strong performance against Lucentis in wAMD suggests it has potential to become standard of care in the other retinal disease indications too.Analysts believe that given the scale of Eylea´s incursion into the wAMD space there is at present no obvious reason that it should not capture the broader retinal disease market from Lucentis. If Eylea achieves the same patient share in RVO, DME and CNV secondary to pathological myopia, it will be a multiple blockbuster product by the end of the forecast period.It is anticipated 2013 revenues of US$1292m for Eylea, rising to US$2079m in 2014 with DME added to the product´s label. Between 2012 and 2017 Eylea will achieve a CAGR of 28%, analysts believe, with revenues rising to US$2891m by the end of that year. By this point, Eylea will have captured around 29% of the overall retinal diseases market, which analysts believe is likely to be its high-water-mark as new products and combinations capture market share.Analysts predicts that by 2018 Eylea will have exhausted the main avenues for easily expanding its patient base, and will record more gradual growth in the second half of the forecast period in competition with Lucentis and newer approvals. Between 2018 and 2024, it is anticipated a CAGR of 6% (15% for the 12-year forecast period overall), with Eylea achieving 2024 revenues of US$4475m, and overtaking Lucentis in 2022. By the close of the forecast period, Eylea will hold 27% of the overall market (with Lucentis on 20%).
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.